Industry Focus

Biogen misses out on a huge deal that Novartis completed with AveXis. Plus, Incyte's phase 3 implosion, and what it means for immuno-oncology more broadly.

Direct download: 20180411_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST